• Users Online: 223
  • Home
  • Print this page
  • Email this page
Home Current issue Ahead of print Search About us Editorial board Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2013  |  Volume : 106  |  Issue : 3  |  Page : 194-198

Long-term effect of intravitreal dexamethasone implant (Ozurdex) in the treatment of resistant diabetic macular edema


Department of Ophthalmology, Ain Shams University, Cairo, Egypt

Correspondence Address:
Abdelrahman G Salman
Ain Shams University, 1195 Cairo
Egypt
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/2090-0686.127404

Rights and Permissions

Aim To evaluate the long-term safety and efficacy of Ozurdex in patients with resistant diabetic macular edema. Design A comparative, randomized, prospective, interventional case series. Patients and methods Fifteen patients with bilateral resistant diabetic macular edema were enrolled in this study. Eyes were randomized into right eyes that received intravitreal dexamethasone implant 0.7 mg (Ozurdex) and left eyes that received intravitreal bevacizumab injection 1.25 mg/0.05 ml. Outcome measures included the change in the best-corrected visual acuity (BCVA), the central macular thickness (CMT) on optical coherence tomography, and the intraocular pressure at 6 and 12 months after injection. Repeated injections were given in both groups when needed. Results The mean age of patients was 52.7 ± 2.1 years. The mean duration of diabetes mellitus was 15.2 years. In the Ozurdex group, the preoperative mean CMT was 535.2 μm, which improved to 198 and 230 μm at 6 and 12 months, respectively, and the preoperative mean BCVA was 0.80 log MAR units, which improved to 0.30 and 0.40 log MAR units at 6 and 12 months, respectively, with mean number of injections of 1.8 (range, 1-3) over 1 year. The intravitreal bevacizumab injection group improved from a mean preoperative CMT of 562.4 to 212 and 266 μm at 6 and 12 months, respectively, and the preoperative mean BCVA was 0.70 log MAR units, which improved to 0.30 and 0.40 log MAR units at 6 and 12 months, respectively, with mean number of injections of 5.4 (range, 4-8) over 1 year. Conclusion Ozurdex is an effective and safe alternative tool in the management of resistant diabetic macular edema. It can be considered as an off-label treatment with less frequent injection than intravitreal bevacizumab injection. Larger multicenter studies with a longer follow-up period are required.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1436    
    Printed29    
    Emailed1    
    PDF Downloaded149    
    Comments [Add]    

Recommend this journal